The PSMA2 (Proteasome Subunit Alpha 2) antibody is a tool used to detect the α2 subunit of the 20S proteasome, a core component of the ubiquitin-proteasome system responsible for intracellular protein degradation. PSMA2. encoded by the *PSMA2* gene, forms part of the catalytic chamber of the proteasome, playing a critical role in maintaining cellular homeostasis by regulating protein turnover. Dysregulation of proteasome activity is linked to various diseases, including cancer, neurodegenerative disorders, and autoimmune conditions, making PSMA2 a research focus in these areas.
PSMA2 antibodies are widely employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study proteasome expression, localization, and function in different tissues or disease models. They are essential for investigating proteasome dynamics under stress, drug treatments, or genetic modifications. Commercially available antibodies are typically raised in rabbits or mice, validated for specificity through knockdown/knockout controls or peptide blocking assays.
Research using PSMA2 antibodies has contributed to understanding proteasome involvement in cancer progression, where elevated proteasome activity often correlates with tumor aggressiveness and drug resistance. Additionally, studies explore its role in neurodegenerative diseases like Alzheimer’s, characterized by abnormal protein aggregation. These antibodies also aid in evaluating proteasome inhibitors’ therapeutic efficacy, such as bortezomib in multiple myeloma. Overall, PSMA2 antibodies are vital for advancing both basic and translational research on protein homeostasis mechanisms.